Chee Tao Chang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Chee Tao Chang has a total of 224 co-authors. Here are the top co-authors by number of shared publications:
Philip Rajan
Clinical Research Centre, Hospital Raja Permaisuri Bainun, Ministry of Health , 30450 Ipoh, Perak
14 shared publications- Chii-Chii Chew
Hospital Raja Permaisuri Bainun
9 shared publications - Jason Choong Yin Lee
Ministry of Health
9 shared publications - Xin Jie Lim
Clinical Research Centre, Hospital Raja Permaisuri Bainun, Ministry of Health, Ipoh, Perak, Malaysia
8 shared publications - Philip Rajan
Department of Otorhinolaryngology, Hospital Raja Permaisuri Bainun, Ipoh, Perak, Malaysia
7 shared publications Huan-Keat Chan
National Institute of Health, Ministry of Health Malaysia
6 shared publications
Latest Publications
- Open Access
- 20 October 2026
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 10, e101650
Knowledge, Attitudes, and Practices of Malaysian Pharmacists Regarding AI Adoption: Cross-Sectional Study
Background: AI is increasingly integrated into health care systems worldwide, with growing implications for pharmacy practice. Although studies have reported general perceptions of AI, gaps between awareness and practical implementation remain evident, particularly in middle-income settings. Objective: This study aimed to assess the baseline knowledge, attitudes, and practices (KAP) of Malaysian pharmacists regarding AI adoption in pharmacy practice and identify factors associated with these domains. Methods: A cross-sectional study was conducted using a self-administered online questionnaire distributed to registered pharmacists practicing in Malaysia. The instrument comprised 12 knowledge items, 10 attitude items, and 5 practice items and underwent expert review and pilot testing. KAP scores were categorized using Bloom cutoff points as good (80%-100%), moderate (60%-79%), or poor (<60%). Data were analyzed using R statistical software. Results: A total of 407 pharmacists completed the survey. The median knowledge score was 75 (IQR 67-92), with 42.3% (172/407) of pharmacists demonstrating good knowledge. The median attitude score was 82 (IQR 76-94), and 64.6% (263/407) of pharmacists exhibited positive attitudes toward AI. However, the median practice score was 56 (IQR 44-68), with 54.3% (221/407) of pharmacists classified as having poor AI use in practice. Statistically significant but weak positive correlations were observed among the 3 domains. Pharmacists with postgraduate qualifications demonstrated significantly higher knowledge scores (P=.01). Conclusions: Malaysian pharmacists demonstrated moderate knowledge and positive attitudes toward AI. However, the practical integration of AI into routine pharmacy workflows remained limited. Strengthening institutional support, structured training, and implementation frameworks may be necessary to translate perceived readiness into clinical adoption.
- 20 October 2026
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 10, e101650
Open AccessKnowledge, Attitudes, and Practices of Malaysian Pharmacists Regarding AI Adoption: Cross-Sectional Study
Background: AI is increasingly integrated into health care systems worldwide, with growing implications for pharmacy practice. Although studies have reported general perceptions of AI, gaps between awareness and practical implementation remain evident, particularly in middle-income settings. Objective: This study aimed to assess the baseline knowledge, attitudes, and practices (KAP) of Malaysian pharmacists regarding AI adoption in pharmacy practice and identify factors associated with these domains. Methods: A cross-sectional study was conducted using a self-administered online questionnaire distributed to registered pharmacists practicing in Malaysia. The instrument comprised 12 knowledge items, 10 attitude items, and 5 practice items and underwent expert review and pilot testing. KAP scores were categorized using Bloom cutoff points as good (80%-100%), moderate (60%-79%), or poor (<60%). Data were analyzed using R statistical software. Results: A total of 407 pharmacists completed the survey. The median knowledge score was 75 (IQR 67-92), with 42.3% (172/407) of pharmacists demonstrating good knowledge. The median attitude score was 82 (IQR 76-94), and 64.6% (263/407) of pharmacists exhibited positive attitudes toward AI. However, the median practice score was 56 (IQR 44-68), with 54.3% (221/407) of pharmacists classified as having poor AI use in practice. Statistically significant but weak positive correlations were observed among the 3 domains. Pharmacists with postgraduate qualifications demonstrated significantly higher knowledge scores (P=.01). Conclusions: Malaysian pharmacists demonstrated moderate knowledge and positive attitudes toward AI. However, the practical integration of AI into routine pharmacy workflows remained limited. Strengthening institutional support, structured training, and implementation frameworks may be necessary to translate perceived readiness into clinical adoption.
- Open Access
- 28 September 2026
- Published by Taylor & Francis in Journal of Pharmaceutical Policy and Practice
- Vol. 19 (1)
In-hospital antimicrobial use and multidrug-resistant infections among COVID-19 patients in Northern Malaysia (COVAM): a multicentre study
Although early uncertainty prompted widespread empirical antimicrobial use, evidence shows low bacterial co-infection rates in COVID-19 patients (3.8–7.4%, 8.0% in Intensive Care Unit [ICU]) alongs...
- 28 September 2026
- Published by Taylor & Francis in Journal of Pharmaceutical Policy and Practice
- Vol. 19 (1)
Open AccessIn-hospital antimicrobial use and multidrug-resistant infections among COVID-19 patients in Northern Malaysia (COVAM): a multicentre study
Although early uncertainty prompted widespread empirical antimicrobial use, evidence shows low bacterial co-infection rates in COVID-19 patients (3.8–7.4%, 8.0% in Intensive Care Unit [ICU]) alongs...
- Open Access
- 2 July 2026
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 22 (11) , 972-979
Mapping global evidence on pharmacy-based colorectal cancer screening initiatives in community settings: A scoping review
- 2 July 2026
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 22 (11) , 972-979
Open AccessMapping global evidence on pharmacy-based colorectal cancer screening initiatives in community settings: A scoping review
- 26 May 2026
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 57 (1)
Colorectal Cancer Screening in Malaysia: Understanding the iFOBT-to-Colonoscopy Gap
Colorectal cancer (CRC) remains a major public health burden in Malaysia. Although the national immunochemical faecal occult blood test (iFOBT) screening programme has expanded substantially in recent years, completion of diagnostic colonoscopy following a positive iFOBT result remains persistently low. This commentary examines the persistent iFOBT-to-colonoscopy gap in Malaysia and proposes an integrated conceptual framework to guide interventions that improve diagnostic follow-up. National and community-based studies demonstrate increasing iFOBT uptake but consistently suboptimal colonoscopy completion rates despite meaningful detection of colorectal cancer and polyps. Existing evidence suggests that fear, procedural anxiety, financial and logistical barriers, poor awareness, fragmented referral systems, and weak care coordination contribute to attrition along the screening pathway. To address these challenges, this commentary integrates the Health Belief Model (HBM) with the socio-ecological model (SEM) to illustrate how behavioural beliefs are influenced by interpersonal, organisational, community, and policy-level factors. The framework highlights the importance of coordinated interventions including patient navigation, reminder systems, provider engagement, digital referral tracking, community outreach, and public-private collaboration. Improving colonoscopy completion after positive iFOBT results requires a coordinated multi-level systems approach that addresses both behavioural and structural barriers to strengthen continuity across the CRC screening continuum.
- 26 May 2026
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 57 (1)
Colorectal Cancer Screening in Malaysia: Understanding the iFOBT-to-Colonoscopy Gap
Colorectal cancer (CRC) remains a major public health burden in Malaysia. Although the national immunochemical faecal occult blood test (iFOBT) screening programme has expanded substantially in recent years, completion of diagnostic colonoscopy following a positive iFOBT result remains persistently low. This commentary examines the persistent iFOBT-to-colonoscopy gap in Malaysia and proposes an integrated conceptual framework to guide interventions that improve diagnostic follow-up. National and community-based studies demonstrate increasing iFOBT uptake but consistently suboptimal colonoscopy completion rates despite meaningful detection of colorectal cancer and polyps. Existing evidence suggests that fear, procedural anxiety, financial and logistical barriers, poor awareness, fragmented referral systems, and weak care coordination contribute to attrition along the screening pathway. To address these challenges, this commentary integrates the Health Belief Model (HBM) with the socio-ecological model (SEM) to illustrate how behavioural beliefs are influenced by interpersonal, organisational, community, and policy-level factors. The framework highlights the importance of coordinated interventions including patient navigation, reminder systems, provider engagement, digital referral tracking, community outreach, and public-private collaboration. Improving colonoscopy completion after positive iFOBT results requires a coordinated multi-level systems approach that addresses both behavioural and structural barriers to strengthen continuity across the CRC screening continuum.
- Open Access
- 18 May 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Knowledge, Attitudes, and Practices of Malaysian Pharmacists Regarding AI Adoption: Cross-Sectional Study (Preprint)
BACKGROUND AI is increasingly integrated into health care systems worldwide, with growing implications for pharmacy practice. Although studies have reported general perceptions of AI, gaps between awareness and practical implementation remain evident, particularly in middle-income settings. OBJECTIVE This study aimed to assess the baseline knowledge, attitudes, and practices (KAP) of Malaysian pharmacists regarding AI adoption in pharmacy practice and identify factors associated with these domains. METHODS A cross-sectional study was conducted using a self-administered online questionnaire distributed to registered pharmacists practicing in Malaysia. The instrument comprised 12 knowledge items, 10 attitude items, and 5 practice items and underwent expert review and pilot testing. KAP scores were categorized using Bloom cutoff points as good (80%-100%), moderate (60%-79%), or poor (<60%). Data were analyzed using R statistical software. RESULTS A total of 407 pharmacists completed the survey. The median knowledge score was 75 (IQR 67-92), with 42.3% (172/407) of pharmacists demonstrating good knowledge. The median attitude score was 82 (IQR 76-94), and 64.6% (263/407) of pharmacists exhibited positive attitudes toward AI. However, the median practice score was 56 (IQR 44-68), with 54.3% (221/407) of pharmacists classified as having poor AI use in practice. Statistically significant but weak positive correlations were observed among the 3 domains. Pharmacists with postgraduate qualifications demonstrated significantly higher knowledge scores (P=.01). CONCLUSIONS Malaysian pharmacists demonstrated moderate knowledge and positive attitudes toward AI. However, the practical integration of AI into routine pharmacy workflows remained limited. Strengthening institutional support, structured training, and implementation frameworks may be necessary to translate perceived readiness into clinical adoption.
- 18 May 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessKnowledge, Attitudes, and Practices of Malaysian Pharmacists Regarding AI Adoption: Cross-Sectional Study (Preprint)
BACKGROUND AI is increasingly integrated into health care systems worldwide, with growing implications for pharmacy practice. Although studies have reported general perceptions of AI, gaps between awareness and practical implementation remain evident, particularly in middle-income settings. OBJECTIVE This study aimed to assess the baseline knowledge, attitudes, and practices (KAP) of Malaysian pharmacists regarding AI adoption in pharmacy practice and identify factors associated with these domains. METHODS A cross-sectional study was conducted using a self-administered online questionnaire distributed to registered pharmacists practicing in Malaysia. The instrument comprised 12 knowledge items, 10 attitude items, and 5 practice items and underwent expert review and pilot testing. KAP scores were categorized using Bloom cutoff points as good (80%-100%), moderate (60%-79%), or poor (<60%). Data were analyzed using R statistical software. RESULTS A total of 407 pharmacists completed the survey. The median knowledge score was 75 (IQR 67-92), with 42.3% (172/407) of pharmacists demonstrating good knowledge. The median attitude score was 82 (IQR 76-94), and 64.6% (263/407) of pharmacists exhibited positive attitudes toward AI. However, the median practice score was 56 (IQR 44-68), with 54.3% (221/407) of pharmacists classified as having poor AI use in practice. Statistically significant but weak positive correlations were observed among the 3 domains. Pharmacists with postgraduate qualifications demonstrated significantly higher knowledge scores (P=.01). CONCLUSIONS Malaysian pharmacists demonstrated moderate knowledge and positive attitudes toward AI. However, the practical integration of AI into routine pharmacy workflows remained limited. Strengthening institutional support, structured training, and implementation frameworks may be necessary to translate perceived readiness into clinical adoption.
- Open Access
- 23 December 2025
- Published by Taylor & Francis in Journal of Pharmaceutical Policy and Practice
- Vol. 19 (1)
Experience and practices of doctors towards pharmacist medication reconciliation service in medical wards: a multicentre study in Perak state Malaysia
Medication reconciliation is a key responsibility of ward pharmacists, who work closely with doctors. However, little is known about doctors’ practices in the administration of this service. A cross-sectional survey was conducted with doctors from the medical wards of 14 Perak government hospitals. A validated self-administered questionnaire was used to assess doctors’ demographics, experiences with pharmacist-led medication reconciliation services (13 items) and practices in administering medication reconciliation-related information (8 items). Responses were measured on a 5-point Likert scale. This study explored doctors’ experiences with and utilisation of medication reconciliation services provided by pharmacists in medical wards. The independent t-test and Kruskal–Wallis test were performed to evaluate the associations between the doctor's sociodemographic backgrounds with their experiences and practices towards pharmacist-led medication reconciliation services. A total of 209 doctors responded, with more than half of them being female (60.8%) and medical officers (76.6%). Most respondents agreed that ward pharmacists play an integral role (97.6%), perform quality reconciliation (97.2%), and reduce medication errors (97.1%) during medication reconciliation. The majority frequently expected the pharmacists to provide medication history assessments (90.0%), relied on their medication history assessments during prescribing at admission (88.6%) and discharge (89.0%), and collaborated on reconciliation issues (91.8%). Higher practice scores were observed among medical officers (3.89 ± 0.63, p = 0.01) and those aged >30 years (3.9 ± 0.46, p = 0.04), and those working in wards with ≥30 beds (3.94 ± 0.48, p = 0.02). Doctors demonstrated positive experiences and practices regarding pharmacist-led medication reconciliation services provided by ward pharmacists. These findings suggest that doctors acknowledge the role of pharmacists in medication reconciliation services.
- 23 December 2025
- Published by Taylor & Francis in Journal of Pharmaceutical Policy and Practice
- Vol. 19 (1)
Open AccessExperience and practices of doctors towards pharmacist medication reconciliation service in medical wards: a multicentre study in Perak state Malaysia
Medication reconciliation is a key responsibility of ward pharmacists, who work closely with doctors. However, little is known about doctors’ practices in the administration of this service. A cross-sectional survey was conducted with doctors from the medical wards of 14 Perak government hospitals. A validated self-administered questionnaire was used to assess doctors’ demographics, experiences with pharmacist-led medication reconciliation services (13 items) and practices in administering medication reconciliation-related information (8 items). Responses were measured on a 5-point Likert scale. This study explored doctors’ experiences with and utilisation of medication reconciliation services provided by pharmacists in medical wards. The independent t-test and Kruskal–Wallis test were performed to evaluate the associations between the doctor's sociodemographic backgrounds with their experiences and practices towards pharmacist-led medication reconciliation services. A total of 209 doctors responded, with more than half of them being female (60.8%) and medical officers (76.6%). Most respondents agreed that ward pharmacists play an integral role (97.6%), perform quality reconciliation (97.2%), and reduce medication errors (97.1%) during medication reconciliation. The majority frequently expected the pharmacists to provide medication history assessments (90.0%), relied on their medication history assessments during prescribing at admission (88.6%) and discharge (89.0%), and collaborated on reconciliation issues (91.8%). Higher practice scores were observed among medical officers (3.89 ± 0.63, p = 0.01) and those aged >30 years (3.9 ± 0.46, p = 0.04), and those working in wards with ≥30 beds (3.94 ± 0.48, p = 0.02). Doctors demonstrated positive experiences and practices regarding pharmacist-led medication reconciliation services provided by ward pharmacists. These findings suggest that doctors acknowledge the role of pharmacists in medication reconciliation services.
- Open Access
- 30 June 2025
- Published by Malaysian Pharmacists Society in Malaysian Journal of Pharmacy
- Vol. 1 (11) , 1-3
Embracing Artificial Intelligence in Malaysian Pharmacy Practice: Current Landscape and Future Directions
Artificial intelligence (AI) is gaining global attention for its potential to transform various aspects of care, including healthcare. In pharmacy, AI is
- 30 June 2025
- Published by Malaysian Pharmacists Society in Malaysian Journal of Pharmacy
- Vol. 1 (11) , 1-3
Open AccessEmbracing Artificial Intelligence in Malaysian Pharmacy Practice: Current Landscape and Future Directions
Artificial intelligence (AI) is gaining global attention for its potential to transform various aspects of care, including healthcare. In pharmacy, AI is
- Open Access
- 18 December 2024
- Published by Taylor & Francis in Journal of Pharmaceutical Policy and Practice
- Vol. 17 (1) , 2436896
Comparing Beers, STOPP and MALPIP criteria in detecting potentially inappropriate medications, clinical outcomes, and cost impacts among older Malaysians: a cohort study
Background: Potentially inappropriate medications (PIMs) are associated with adverse outcomes and higher healthcare costs in older adults. Explicit screening criteria like the Beers Criteria, STOPP criteria, and the Malaysian Potentially Inappropriate Prescribing (MALPIP) criteria served to identify PIMs, but comparative data are scarce. Aim: To evaluate the prevalence of PIMs identified by Beers 2019, STOPP version 2 and MALPIP criteria in Malaysian older adults and examine their predictive ability for adverse outcomes and cost-saving potential. Methods: A historical cohort study was conducted among older adults aged ≥ 60 years on five or more medications in four Malaysian tertiary hospitals. PIMs were identified using Beers, STOPP, and MALPIP criteria. Sensitivity, specificity and predictive abilities of these criteria were analysed against clinical outcomes. Monthly cost savings were calculated based on hypothetical deprescribing scenarios. Results: Among 1069 patients, the prevalence of PIMs was 89.1% using MALPIP, 51.3% with Beers, and 37.0% with STOPP criteria. A moderate concordance was seen between Beers and STOPP criteria (κ = 0.437), and the lowest agreement was observed between the STOPP and MALPIP (κ = 0.131). STOPP criteria significantly predicted hospital readmissions (p = 0.003), while Beers and MALPIP did not show significant predictive abilities across all outcomes. The most common PIMs identified were proton pump inhibitors (PPIs) and nonsteroidal anti-inflammatory drugs (NSAIDs). Deprescribing scenarios based on these criteria indicated potential monthly cost savings of MYR 4.83 to MYR 44.84 per patient, with the greatest savings associated with MALPIP criteria. Conclusion: MALPIP demonstrated the highest potential for cost savings, the highest sensitivity but the lowest specificity in PIM detection. Context-specific assessments and clinical judgment are crucial in optimising medication safety and efficacy in geriatric pharmacotherapy. Further research is needed to refine PIM criteria to better predict clinical outcomes and balance the benefits and risks of deprescribing in diverse healthcare settings.
- 18 December 2024
- Published by Taylor & Francis in Journal of Pharmaceutical Policy and Practice
- Vol. 17 (1) , 2436896
Open AccessComparing Beers, STOPP and MALPIP criteria in detecting potentially inappropriate medications, clinical outcomes, and cost impacts among older Malaysians: a cohort study
Background: Potentially inappropriate medications (PIMs) are associated with adverse outcomes and higher healthcare costs in older adults. Explicit screening criteria like the Beers Criteria, STOPP criteria, and the Malaysian Potentially Inappropriate Prescribing (MALPIP) criteria served to identify PIMs, but comparative data are scarce. Aim: To evaluate the prevalence of PIMs identified by Beers 2019, STOPP version 2 and MALPIP criteria in Malaysian older adults and examine their predictive ability for adverse outcomes and cost-saving potential. Methods: A historical cohort study was conducted among older adults aged ≥ 60 years on five or more medications in four Malaysian tertiary hospitals. PIMs were identified using Beers, STOPP, and MALPIP criteria. Sensitivity, specificity and predictive abilities of these criteria were analysed against clinical outcomes. Monthly cost savings were calculated based on hypothetical deprescribing scenarios. Results: Among 1069 patients, the prevalence of PIMs was 89.1% using MALPIP, 51.3% with Beers, and 37.0% with STOPP criteria. A moderate concordance was seen between Beers and STOPP criteria (κ = 0.437), and the lowest agreement was observed between the STOPP and MALPIP (κ = 0.131). STOPP criteria significantly predicted hospital readmissions (p = 0.003), while Beers and MALPIP did not show significant predictive abilities across all outcomes. The most common PIMs identified were proton pump inhibitors (PPIs) and nonsteroidal anti-inflammatory drugs (NSAIDs). Deprescribing scenarios based on these criteria indicated potential monthly cost savings of MYR 4.83 to MYR 44.84 per patient, with the greatest savings associated with MALPIP criteria. Conclusion: MALPIP demonstrated the highest potential for cost savings, the highest sensitivity but the lowest specificity in PIM detection. Context-specific assessments and clinical judgment are crucial in optimising medication safety and efficacy in geriatric pharmacotherapy. Further research is needed to refine PIM criteria to better predict clinical outcomes and balance the benefits and risks of deprescribing in diverse healthcare settings.
- Open Access
- 16 September 2024
- Published by Taylor & Francis in Journal of Pharmaceutical Policy and Practice
- Vol. 17 (1) , 2399727
Factors influencing healthcare providers’ behaviours in deprescribing: a cross-sectional study
Deprescribing serves as a pivotal measure to mitigate the drug-related problem due to polypharmacy. This study aimed to map the factors influencing healthcare providers' deprescribing decision using the Behaviour Change Wheel framework and develop an innovative conceptual model to support deprescribing practice. A cross-sectional online survey targeting doctors and pharmacists was conducted to assess the influence of various factors on healthcare providers' comfort in recommending deprescribing. The conceptual model was formulated, based on the existing deprescribing framework and the Behaviour Change Wheel. The model's robustness was scrutinised through Partial Least Squares Structural Equation Modeling (PLS-SEM), and model-fitting indices were employed to obtain the best-fit model. A total of 736 responses were analysed with the final best-fit model consisting of 24 items in 5 constructs (R 2: 0.163; SRMR: 0.064; rho_c: 0.750-0.862; AVE: 0.509-0.627) and three independent factors. Based on the results, we proposed that deprescribing could be promoted through strategies aimed at enhancing healthcare providers internal capabilities such as knowledge levels, when patients' condition deteriorated and previous experiences with adverse events of drugs. Organisational support in providing such educational opportunities is important, with the empowerment of patient and healthcare providers through policy enhancements, guideline development, and effective communication. The deprescribing behaviours of healthcare professionals are influenced by an intricate interplay of patient, prescriber, and system factors. Enhancing deprescribing practices necessitates a comprehensive strategy that encompasses providers and patients' education, the development of structured deprescribing guidelines, the implementation of deprescribing support tools, and the enhancement of communication between healthcare providers.
- 16 September 2024
- Published by Taylor & Francis in Journal of Pharmaceutical Policy and Practice
- Vol. 17 (1) , 2399727
Open AccessFactors influencing healthcare providers’ behaviours in deprescribing: a cross-sectional study
Deprescribing serves as a pivotal measure to mitigate the drug-related problem due to polypharmacy. This study aimed to map the factors influencing healthcare providers' deprescribing decision using the Behaviour Change Wheel framework and develop an innovative conceptual model to support deprescribing practice. A cross-sectional online survey targeting doctors and pharmacists was conducted to assess the influence of various factors on healthcare providers' comfort in recommending deprescribing. The conceptual model was formulated, based on the existing deprescribing framework and the Behaviour Change Wheel. The model's robustness was scrutinised through Partial Least Squares Structural Equation Modeling (PLS-SEM), and model-fitting indices were employed to obtain the best-fit model. A total of 736 responses were analysed with the final best-fit model consisting of 24 items in 5 constructs (R 2: 0.163; SRMR: 0.064; rho_c: 0.750-0.862; AVE: 0.509-0.627) and three independent factors. Based on the results, we proposed that deprescribing could be promoted through strategies aimed at enhancing healthcare providers internal capabilities such as knowledge levels, when patients' condition deteriorated and previous experiences with adverse events of drugs. Organisational support in providing such educational opportunities is important, with the empowerment of patient and healthcare providers through policy enhancements, guideline development, and effective communication. The deprescribing behaviours of healthcare professionals are influenced by an intricate interplay of patient, prescriber, and system factors. Enhancing deprescribing practices necessitates a comprehensive strategy that encompasses providers and patients' education, the development of structured deprescribing guidelines, the implementation of deprescribing support tools, and the enhancement of communication between healthcare providers.